Research & Development to Product Development

SARAWAK BIODIVERSITY CENTRE (SBC), SARAWAK, 27 SEPTEMBER 2026 —

Sarawak Biodiversity Centre Launches End-to-End Pipeline to Commercialise Indigenous Knowledge into Global Health Products

The Sarawak Biodiversity Centre (SBC) has unveiled a fully integrated, multi-disciplinary workflow designed to convert the state’s unparalleled biological diversity into scientifically validated, ethically sourced, and commercially viable products for global health markets—while ensuring indigenous communities retain economic benefits from conservation efforts.

The initiative marks a rare convergence of traditional knowledge, cutting-edge biotechnology, and sustainable supply-chain management, positioning Sarawak as a potential hub for high-value natural product development in Southeast Asia. Unlike conventional bioprospecting models, SBC’s approach embeds indigenous expertise at every stage, from initial discovery to large-scale production, while enforcing strict ecological safeguards to prevent resource depletion.

At the core of SBC’s strategy is bioprospecting, a process that begins with partnerships between the centre and Sarawak’s indigenous communities. Through ethnobiological research, SBC documents traditional knowledge systems to identify biological resources—plants, microbes, and fungi—with unique bioactive properties. These findings are cross-referenced with SBC’s Natural Product Library, a repository housing thousands of extracts and specialised microbial strains, which serve as the raw material for further scientific evaluation.

Once potential leads are identified, they undergo high-throughput screening to isolate compounds with therapeutic promise, such as antimicrobial, anti-inflammatory, or specialised anti-cancer properties. Successful candidates are then subjected to precision profiling in SBC’s Molecular Biology and Analytical Chemistry laboratories. Using advanced tools like Gas Chromatography-Mass Spectrometry (GCMS), scientists map the exact chemical structures of bioactive compounds, ensuring purity and reproducibility.

Genetic sequencing further refines the process by decoding the genetic makeup of source organisms, enabling consistent replication of active ingredients—a critical step for scalability.

The transition from raw science to market-ready products occurs in SBC’s Product Development Lab, where formulations are engineered for consumer use. Stability testing evaluates how extracts perform under varying environmental conditions, guaranteeing long shelf life and consistent efficacy. Specialised development teams then create standardised products, including herbal extracts, essential oil blends, and topical treatments tailored for dermatological or general healthcare applications.

Unlike many natural product ventures, SBC’s model prioritises scalability without ecological compromise, balancing industrial standards with community-led conservation.

Central to this approach is the Good Wild Craft Practices (GWCP) framework, a set of guidelines that govern the sustainable harvesting of biological resources. Under GWCP, only specific plant parts are collected at optimal times to ensure mother plants regenerate, while indigenous communities—who serve as primary suppliers—adhere to protocols that prevent contamination and preserve bioactive compound potency. Economic benefits flow directly to these communities, reinforcing incentives for long-term conservation.

While SBC has not disclosed specific product launches or revenue figures, the centre’s structured pipeline—spanning discovery, validation, formulation, and ethical sourcing—aligns with growing global demand for nature-based therapeutics, particularly in pharmaceuticals, cosmeceuticals, and functional foods. The model also addresses a critical gap in Malaysia’s bioeconomy: the lack of a cohesive, science-backed system to monetise biodiversity while mitigating exploitation risks.

With Sarawak’s ecosystems ranking among the most biodiverse on Earth, SBC’s initiative could serve as a blueprint for other resource-rich regions in Southeast Asia seeking to leverage their natural capital sustainably.

The next phase for SBC will likely involve pilot-scale production partnerships with pharmaceutical or cosmetics firms, as well as potential collaborations with Malaysian research institutions to expand genetic and chemical databases. The centre’s emphasis on community ownership and GWCP compliance may also attract certifications from international sustainability standards, further enhancing market access. For now, the focus remains on refining the workflow—from forest to formulary—before scaling commercial outputs.